• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.老年综合评估测量的功能状态预测老年异基因造血细胞移植受者生存不良。
Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196. doi: 10.1016/j.bbmt.2019.08.022. Epub 2019 Sep 5.
2
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.老年异基因造血干细胞移植受者的老年评估:功能和认知障碍与预后的关联。
Blood Adv. 2020 Jun 23;4(12):2810-2820. doi: 10.1182/bloodadvances.2020001719.
3
Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.老年患者异基因造血细胞移植后功能下降的模式和预测因素。
Transplant Cell Ther. 2022 Jun;28(6):309.e1-309.e9. doi: 10.1016/j.jtct.2022.02.022. Epub 2022 Mar 3.
4
Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults.异基因造血干细胞移植前老年人药物滥用的影响。
Transplant Cell Ther. 2021 Apr;27(4):344.e1-344.e5. doi: 10.1016/j.jtct.2021.01.001. Epub 2021 Jan 7.
5
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.CD34 分选异基因造血干细胞移植治疗多发性骨髓瘤的保前国际分期系统分期和其他重要结局相关性。
Biol Blood Marrow Transplant. 2020 Jan;26(1):58-65. doi: 10.1016/j.bbmt.2019.08.023. Epub 2019 Sep 5.
6
The Prevalence of Pretransplant Frailty and Mental Distress in Hematopoietic Cell Transplantation and Association with Clinical Outcomes.造血细胞移植患者移植前衰弱和精神困扰的发生率及其与临床结局的关系。
Transplant Cell Ther. 2024 Sep;30(9):919.e1-919.e9. doi: 10.1016/j.jtct.2024.05.026. Epub 2024 Jun 3.
7
Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis.老年异基因造血细胞移植受者的老年评估与生活质量:一项前瞻性危险因素及系列评估分析
Bone Marrow Transplant. 2018 May;53(5):565-575. doi: 10.1038/s41409-017-0021-4. Epub 2018 Jan 12.
8
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.移植前肾功能不全对异基因造血细胞移植后结局的影响。
Transplant Cell Ther. 2021 May;27(5):410-422. doi: 10.1016/j.jtct.2021.02.030. Epub 2021 Feb 26.
9
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.老年评估以预测老年异基因造血细胞移植受者的生存率。
Haematologica. 2014 Aug;99(8):1373-9. doi: 10.3324/haematol.2014.103655. Epub 2014 May 9.
10
Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults.老年综合评估和全球衰弱与老年异体造血细胞移植后认知功能下降的相关性。
J Geriatr Oncol. 2023 Nov;14(8):101623. doi: 10.1016/j.jgo.2023.101623. Epub 2023 Sep 6.

引用本文的文献

1
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies.老年血液系统恶性肿瘤患者的异基因造血干细胞移植
Yonago Acta Med. 2025 Jul 17;68(3):169-179. doi: 10.33160/yam.2025.08.001. eCollection 2025 Aug.
2
Prognostic Value of Geriatric Characteristics in Allogeneic Haematopoietic Stem Cell Transplant Recipients Aged Over 60 Years.老年特征在60岁以上异基因造血干细胞移植受者中的预后价值
EJHaem. 2025 Aug 1;6(4):e70115. doi: 10.1002/jha2.70115. eCollection 2025 Aug.
3
Allogeneic Transplantation for Older Adults.老年人的异体移植
Adv Exp Med Biol. 2025;1475:9-40. doi: 10.1007/978-3-031-84988-6_2.
4
Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies.老年评估在造血干细胞移植和细胞治疗中的作用。
Curr Treat Options Oncol. 2025 May;26(5):348-359. doi: 10.1007/s11864-025-01316-6. Epub 2025 Apr 10.
5
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.70岁以上成人急性髓系白血病的异基因造血细胞移植
Blood. 2025 Jun 12;145(24):2847-2856. doi: 10.1182/blood.2024024247.
6
Health professionals' perceptions of prehabilitation before haematopoietic cell transplantation to optimise candidacy in older adults.健康专业人员对血液细胞移植前康复的看法,以优化老年人的候选资格。
Support Care Cancer. 2024 Jun 26;32(7):465. doi: 10.1007/s00520-024-08659-0.
7
Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies.异基因骨髓移植治疗淋巴恶性肿瘤患者的供者克隆性造血。
Blood Adv. 2024 Jul 23;8(14):3849-3858. doi: 10.1182/bloodadvances.2023011761.
8
Transplantation and Cellular Therapy for Older Adults-The MSK Approach.老年人的移植和细胞治疗——MSK 方法。
Curr Hematol Malig Rep. 2024 Apr;19(2):82-91. doi: 10.1007/s11899-024-00725-y. Epub 2024 Feb 9.
9
Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.个性化医疗时代慢性淋巴细胞白血病的治疗
Pharmaceutics. 2023 Dec 29;16(1):55. doi: 10.3390/pharmaceutics16010055.
10
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.预处理脆弱表型影响老年异基因移植受者的生存和复发。
Transplant Cell Ther. 2024 Apr;30(4):415.e1-415.e16. doi: 10.1016/j.jtct.2024.01.062. Epub 2024 Jan 17.

本文引用的文献

1
Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.血液系统恶性肿瘤老年患者的步态速度、握力和临床结局。
Blood. 2019 Jul 25;134(4):374-382. doi: 10.1182/blood.2019000758. Epub 2019 Jun 5.
2
Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience.造血细胞移植中移植前综合老年评估:单中心经验
Bone Marrow Transplant. 2018 Sep;53(9):1184-1187. doi: 10.1038/s41409-018-0151-3. Epub 2018 Mar 9.
3
Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis.老年异基因造血细胞移植受者的老年评估与生活质量:一项前瞻性危险因素及系列评估分析
Bone Marrow Transplant. 2018 May;53(5):565-575. doi: 10.1038/s41409-017-0021-4. Epub 2018 Jan 12.
4
Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful.移植中集中式患者报告结局数据收集是可行的且具有临床意义。
Cancer. 2017 Dec 1;123(23):4687-4700. doi: 10.1002/cncr.30936. Epub 2017 Aug 17.
5
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.在美国,70岁及以上患者中异基因造血细胞移植的使用越来越多。
Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. Epub 2017 Jul 3.
6
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.年龄≥70岁的骨髓增生异常综合征患者的异基因干细胞移植:欧洲血液与骨髓移植协会慢性恶性肿瘤工作组骨髓增生异常综合征小组委员会的一项回顾性研究
Biol Blood Marrow Transplant. 2017 Jan;23(1):44-52. doi: 10.1016/j.bbmt.2016.09.027. Epub 2016 Oct 5.
7
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.采用减低剂量预处理方案对首次完全缓解的老年急性髓系白血病患者进行异基因移植的II期研究:癌症与白血病B组100103(肿瘤临床试验联盟)/血液与骨髓移植临床试验网络0502的结果
J Clin Oncol. 2015 Dec 10;33(35):4167-75. doi: 10.1200/JCO.2015.62.7273. Epub 2015 Nov 2.
8
Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).患者报告的身体功能可预测造血细胞移植的成功率(BMT CTN 0902)。
Cancer. 2016 Jan 1;122(1):91-8. doi: 10.1002/cncr.29717. Epub 2015 Oct 6.
9
Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates.老年异基因造血细胞移植候选者中进行老年评估的最佳筛查。
J Geriatr Oncol. 2014 Oct 1;5(4):422-30. doi: 10.1016/j.jgo.2014.04.004. Epub 2014 May 14.
10
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.老年评估以预测老年异基因造血细胞移植受者的生存率。
Haematologica. 2014 Aug;99(8):1373-9. doi: 10.3324/haematol.2014.103655. Epub 2014 May 9.

老年综合评估测量的功能状态预测老年异基因造血细胞移植受者生存不良。

Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.

机构信息

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

出版信息

Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196. doi: 10.1016/j.bbmt.2019.08.022. Epub 2019 Sep 5.

DOI:10.1016/j.bbmt.2019.08.022
PMID:31493541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6942208/
Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) has been increasingly offered to older adults with hematologic malignancies. However, optimal methods to determine fitness for alloHCT have yet to be defined. We evaluated the ability of a comprehensive geriatric assessment (CGA) to predict post-alloHCT outcomes in a single-center prospective cohort study of patients age 50 years and older. Outcomes included overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM). A total of 148 patients were included, with a median age of 62 years (range, 50 to 76 years). In multivariate regression analysis, several CGA measures of functional status were predictive of post-alloHCT outcomes, after adjusting for traditional prognostic factors. Any deficit in instrumental activities of daily living (IADL) was associated with inferior OS (hazard ratio [HR], 1.81, 95% confidence interval [CI], 1.07 to 3.08; P = .03) and PFS (HR, 1.85; 95% CI, 1.15 to 2.99; P = .01). A Medical Outcomes Study Physical Health scale (MOS-PH) score <85 was associated with inferior OS (HR, 1.96; 95% CI, 1.13 to 3.40; P = .02), PFS (HR, 1.75; 95% CI, 1.07 to 2.88; P = .03), and increased NRM (subdistribution HR, 2.57; 95% CI, 1.12 to 5.92; P = .03). MOS-PH score was also associated with the number of non-hematologic grade ≥3 adverse events within the first 100 days after alloHCT (rate ratio, 1.61; 95% CI, 1.04 to 2.49; P = .03). These findings support previous work suggesting that IADL is an important prognostic tool prior to alloHCT. MOS-PH is newly identified as an additional metric to identify older patients at higher risk of poor post-alloHCT outcomes, including toxicity and NRM.

摘要

异基因造血细胞移植(alloHCT)已越来越多地用于老年血液系统恶性肿瘤患者。然而,确定 alloHCT 适宜性的最佳方法尚未确定。我们评估了综合老年评估(CGA)在单中心前瞻性队列研究中预测 50 岁及以上患者 alloHCT 后结局的能力。结局包括总生存(OS)、无进展生存(PFS)和非复发死亡率(NRM)。共纳入 148 例患者,中位年龄 62 岁(范围 50 至 76 岁)。在多变量回归分析中,调整传统预后因素后,几项 CGA 功能性状态测量指标与 alloHCT 后结局相关。任何日常生活活动(IADL)的缺陷与较差的 OS(风险比[HR],1.81,95%置信区间[CI],1.07 至 3.08;P =.03)和 PFS(HR,1.85;95% CI,1.15 至 2.99;P =.01)相关。医学结局研究身体健康量表(MOS-PH)评分<85 与较差的 OS(HR,1.96;95% CI,1.13 至 3.40;P =.02)、PFS(HR,1.75;95% CI,1.07 至 2.88;P =.03)和增加的 NRM(亚分布 HR,2.57;95% CI,1.12 至 5.92;P =.03)相关。MOS-PH 评分也与 alloHCT 后 100 天内非血液学≥3 级不良事件的数量相关(率比,1.61;95% CI,1.04 至 2.49;P =.03)。这些发现支持先前的工作,表明 IADL 是 alloHCT 前重要的预后工具。MOS-PH 是新确定的另一个指标,用于识别 alloHCT 后结局较差(包括毒性和 NRM)风险较高的老年患者。